Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

GILEAD Aktie

 >GILEAD Aktienkurs 
139.24 EUR    -0.8%    (TradegateBSX)
Ask: 139.06 EUR / 70 Stück
Bid: 138.92 EUR / 70 Stück
Tagesumsatz: 1766 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
GILEAD Aktie über LYNX handeln
>GILEAD Performance
1 Woche: +3,3%
1 Monat: +8,5%
3 Monate: +17,0%
6 Monate: +18,8%
1 Jahr: +38,0%
laufendes Jahr: +31,3%
>GILEAD Aktie
Name:  GILEAD SCIENCES DL-,001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US3755581036 / 885823
Symbol/ Ticker:  GIS (Frankfurt) / GILD (NASDAQ)
Kürzel:  FRA:GIS, ETR:GIS, GIS:GR, NASDAQ:GILD
Index:  S&P500, Nasdaq100
Profil:  Gilead Sciences Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious and life-threatening diseases. Its current business centers on virology, oncology, and inflammation, with a particularly..
>Volltext..
Marktkapitalisierung:  173617.87 Mio. EUR
Unternehmenswert:  192220.28 Mio. EUR
Umsatz:  27176.43 Mio. EUR
EBITDA:  13049.92 Mio. EUR
Nettogewinn:  -2882.78 Mio. EUR
Gewinn je Aktie:  -2.32 EUR
Schulden:  23352.3 Mio. EUR
Liquide Mittel:  2828.51 Mio. EUR
Operativer Cashflow:  12057.85 Mio. EUR
Bargeldquote:  0.44
Umsatzwachstum:  9.39%
Gewinnwachstum:  -152.95%
Dividende je Aktie:  2.8 EUR
Dividendenrendite:  2.07%
Dividendenschätzung:  2.1%
Div. Historie:  15.09.26 - 0.710366€
15.06.26 - 0.707578€
>weitere anzeigen...
Insiderhandel:  3 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 2.807.888 Euro.
Suchwörter:  GILEAD, REMDESIVIR
Letzte Datenerhebung:  18.10.26
>GILEAD Kennzahlen
Aktien/ Unternehmen:
Aktien: 1239.96 Mio. St.
Frei handelbar: 99.84%
Rückkaufquote: 0.58%
Mitarbeiter: 17000
Umsatz/Mitarb.: 1.54 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 3.89%
Bewertung:
KGV: -
KGV lG: -
KUV: 6.47
KBV: 16.64
PEG-Ratio: -
EV/EBITDA: 14.73
Rentabilität:
Bruttomarge: 79.66%
Gewinnmarge: -10.61%
Operative Marge: 39.05%
Managementeffizenz:
Gesamtkaprendite: -6.17%
Eigenkaprendite: -20.57%
 >GILEAD Anleihen 
>GILEAD Peer Group
 
16.10.26 - 23:01
Insiderhandel: Chief Financial Officer verkauft Aktien von Gilead Sciences im Wert von 468660 USD (Insiderkauf)
 
Dickinson, Andrew D. - Vorstand - Tag der Transaktion: 2026-10-15...
16.10.26 - 01:45
Gilead Sciences (GILD) Rises Higher Than Market: Key Facts (Zacks)
 
Gilead Sciences (GILD) closed the most recent trading day at $157.48, moving +2.57% from the previous trading session....
15.10.26 - 22:09
Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 (Business Wire)
 
FOSTER CITY, Calif.--(BUSINESS WIRE)--#Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2026 financial results and guidance will be released on Thursday, October 29, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's third quarter 2026 financial results and provide a business update. A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. For more informatio...
15.10.26 - 22:00
Can Gilead′s Deal With VIR Boost Its Oncology Pipeline and Growth? (Zacks)
 
Gilead Sciences expands its oncology pipeline through a Vir Biotechnology deal worth up to $1.74 billion in additional milestones, targeting three novel cancer therapies....
15.10.26 - 20:31
Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets (MarketWatch)
 
Shares of AbbVie, Eli Lilly and Gilead Sciences are trading at or near record highs....
14.10.26 - 15:15
Vir jumps on Gilead licensing deal worth up to $1.9B for cancer drugs (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
13.10.26 - 13:48
Earnings Preview: What to Expect From Gilead Sciences' Report (Barchart)
 
Um den gesamten Artikel unter newsbreak.com zu lesen, klicken Sie bitte auf die Überschrift...
10.10.26 - 01:45
Gilead Sciences (GILD) Laps the Stock Market: Here′s Why (Zacks)
 
Gilead Sciences (GILD) closed the most recent trading day at $151.17, moving +2.77% from the previous trading session....
07.10.26 - 13:45
Exklusiv: Gilead Sciences plant HSV-Weltpremiere am 24. Oktober (Sharedeals)
 
Am 24. Oktober könnte Gilead auf der IDWeek 2026 in Washington erstmals zeigen, wie groß man das HSV-Geschäft tatsächlich denkt. Nach exklusiven sharedeals.de-Informationen plant Gilead an diesem Tag Updates zu seinem von Assembly Biosciences einlizenzierten HSV-Programm. Hinter bloßen Studiendaten könnte eine wesentlich größere Story stehen: der Aufbau einer neuen Multi-Milliarden-Franchise neben HIV. Die IDWeek ist […] The post Exklusiv: Gilead Sciences plant HSV-Weltpremiere am 24. Oktober first appeared on sharedeals.de....
07.10.26 - 11:48
Gilead Sciences signs five-year DevOps agreement with Cognizant (PBR)
 
The renewed arrangement will see Cognizant combine its life sciences sector knowledge with technical services to aid Gilead's ongoing development and operational processes. The joint work is intended The post Gilead Sciences signs five-year DevOps agreement with Cognizant appeared first on Pharmaceutical Business review....
05.10.26 - 13:01
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences (GlobeNewswire EN)
 
Two-year extension builds on productive relationship established in 2019...
03.10.26 - 01:45
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know (Zacks)
 
Gilead Sciences (GILD) closed the most recent trading day at $144.74, moving 1.87% from the previous trading session....
03.10.26 - 01:01
Insiderhandel: Chairman & CEO verkauft Aktien von Gilead Sciences im Wert von 2218508 USD (Insiderkauf)
 
O'day, Daniel Patrick - Vorstand - Tag der Transaktion: 2026-10-01...
01.10.26 - 16:45
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
 
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock....
01.10.26 - 01:45
Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors (Zacks)
 
In the latest trading session, Gilead Sciences (GILD) closed at $149.45, marking a -1.21% move from the previous day....
29.09.26 - 15:06
Former Gilead CIO and CSL Chief Digital & Information Officer Mark Hill Joins Sware Board of Directors (Business Wire)
 
Sware gains 35 years of pharma technology leadership as life sciences organizations modernize validation for the AI eraBOSTON--(BUSINESS WIRE)--Sware, Inc., the company behind the Res_Q, the AI-powered validation platform, and provider of GxP compliance solutions, today announced the appointment of Mark Hill to its Board of Directors. Hill has spent more than 35 years leading information and technology across the pharmaceutical and life sciences industry, working with CEOs, boards, and executive teams through growth, disruption, acquisition, and modernization. He is Executive Vice President and Chief Digital & Information Officer at CSL Limited. Before CSL, he was CIO of Gilead Sciences and held senior technology leadership roles at Merck and Schering-Plough. He served as Independent Director of Puppet through its acquisition by Perforce Software and has advised Tricentis, Zapata Quantum, and Iridius.ai. Hill is a United States Army veteran. His appointment comes as life sciences companies move quickly to...
23.09.26 - 11:00
Gilead Sciences und Assembly Bio: Kommt am 13. Oktober der Herpes-Paukenschlag? (Sharedeals)
 
Bei Gilead Sciences verdichten sich derzeit die Hinweise darauf, dass der Pharmakonzern in den kommenden Jahren das Therapiefeld der Virologie massiv ausbauen und damit die langfristige Abhängigkeit vom HIV-Geschäft minimieren will. Die Hintergründe könnten auch für Anleger spannender kaum sein. Eine neue Stellenanzeige, die langjährige Partnerschaft mit Assembly Biosciences, bereits einlizenzierte Helicase-Primase-Inhibitoren und Aussagen von […] The post Gilead Sciences und Assembly Bio: Kommt am 13. Oktober der Herpes-Paukenschlag? first appeared on sharedeals.de....
23.09.26 - 01:45
Gilead Sciences (GILD) Stock Moves 1.40%: What You Should Know (Zacks)
 
Gilead Sciences (GILD) closed the most recent trading day at $152.67, moving +1.4% from the previous trading session....
20.09.26 - 15:06
Why Morgan Stanley likes Gilead′s HIV prevention play (The Street)
 
Morgan Stanley kept Gilead at Overweight after its 2026 Global Healthcare Conference. One franchise stood out from everything management discussed....
17.09.26 - 16:45
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know (Zacks)
 
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Du deutest mehr an als du aussprichst. - Plus significas quam loqueris. - Seneca
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!